Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Lisa Beth Nachtigall, M.D.

Co-Author

This page shows the publications co-authored by Lisa Nachtigall and Alexander Faje.
Connection Strength

1.911
  1. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014 Nov; 99(11):4078-85.
    View in: PubMed
    Score: 0.629
  2. Current treatment options for hyperprolactinemia. Expert Opin Pharmacother. 2013 Aug; 14(12):1611-25.
    View in: PubMed
    Score: 0.581
  3. Biochemical Control in Acromegaly With Multimodality Therapies: Outcomes From a Pituitary Center and Changes Over Time. J Clin Endocrinol Metab. 2020 03 01; 105(3).
    View in: PubMed
    Score: 0.232
  4. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol. 2019 Sep; 181(3):211-219.
    View in: PubMed
    Score: 0.224
  5. Central diabetes insipidus: a previously unreported side effect of temozolomide. J Clin Endocrinol Metab. 2013 Oct; 98(10):3926-31.
    View in: PubMed
    Score: 0.147
  6. Low Plasma Oxytocin Levels and Increased Psychopathology in Hypopituitary Men With Diabetes Insipidus. J Clin Endocrinol Metab. 2019 08 01; 104(8):3181-3191.
    View in: PubMed
    Score: 0.056
  7. Accuracy of Late-Night Salivary Cortisol in Evaluating Postoperative Remission and Recurrence in Cushing's Disease. J Clin Endocrinol Metab. 2015 Oct; 100(10):3770-7.
    View in: PubMed
    Score: 0.042
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.